Preclinical and clinical researchers in the Melanoma Program advance the Program mission to study all aspects of melanoma and translate the findings into actionable diagnostic, preventative, and therapeutic opportunities that will improve the lives of patients and contribute to our understanding of the disease.
The Specific Aims of the Program are: 1) To understand the molecular pathogenesis of melanoma, including genomics, epigenomics, metabolomics, and utilize this information for optimal therapeutic targeting; 2) To understand tumor-host interactions and utilize this information to optimize therapeutic strategies that target the tumor microenvironment; and 3) To understand the external environmental factors that modulate melanoma risk and carcinogenesis, as well as the human behaviors associated with melanoma formation. The program has 44 members, representing six DF/HCC institutions and seven academic departments. In 2014 peer- reviewed grant funding attributed to the Program was $3.7 million in total costs from the NCI and $1.6 million from other sponsors. During the current funding period, Melanoma Program members published 873 cancer- relevant papers. Of these 30% were inter-institutional, 21% were intra-programmatic, and 39% were inter- programmatic collaborations between two or more DF/HCC members. Overall, when counted once, 27% of DF/HCC publications were inter-programmatic collaborations.
|Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :|
|Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351|
|Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231|
|Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199|
|Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945|
|Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:|
|Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534|
|Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583|
|Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404|
|Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917|
Showing the most recent 10 out of 411 publications